Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
88.98
+1.73 (1.98%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -178.92 | -155.2 | -208.02 | -338.79 | -83.82 | -65.8 |
Depreciation & Amortization | - | - | - | 0.96 | 1.96 | 2 |
Loss (Gain) From Sale of Assets | -70 | -10 | - | -15.53 | - | - |
Asset Writedown & Restructuring Costs | - | - | - | 132.77 | - | - |
Loss (Gain) From Sale of Investments | -8.59 | -8.09 | -11.4 | -2.32 | -0.33 | 0.55 |
Stock-Based Compensation | 45.7 | 37.61 | 44.83 | 25.68 | 7.11 | 8.04 |
Other Operating Activities | 7.96 | -27.64 | 21.71 | 102.53 | 0.43 | -0.34 |
Change in Accounts Receivable | - | - | - | 0.38 | 0.44 | -0.82 |
Change in Accounts Payable | 2.03 | 7.65 | -16.21 | -2.18 | -2.64 | 1.07 |
Change in Unearned Revenue | - | - | - | 0.58 | -0.88 | 3.58 |
Change in Other Net Operating Assets | -7.12 | -13.58 | 11.68 | -3.97 | -2.42 | -1.99 |
Operating Cash Flow | -208.94 | -169.25 | -157.41 | -99.91 | -80.14 | -53.72 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | - | - | -0.04 | -0.57 |
Sale of Property, Plant & Equipment | - | - | - | 0.48 | - | - |
Cash Acquisitions | - | - | - | 3.04 | - | - |
Sale (Purchase) of Intangibles | 70 | 7 | - | 15 | - | - |
Investment in Securities | -533.74 | -150.48 | -353.29 | -126.9 | 57.05 | -22.05 |
Investing Cash Flow | -463.74 | -143.48 | -353.29 | -108.39 | 57.01 | -22.62 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | - | - | - | -0.42 | -0.51 |
Net Debt Issued (Repaid) | - | - | - | - | -0.42 | -0.51 |
Issuance of Common Stock | 781.73 | 314.44 | 243.89 | 84.96 | 43.1 | 1.9 |
Other Financing Activities | -28.71 | -5.41 | -1.84 | -5.8 | - | - |
Financing Cash Flow | 753.03 | 309.03 | 410.91 | 361.08 | 42.68 | 1.39 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | - | - | -0 | 0.03 | -0.11 | -0.02 |
Net Cash Flow | 80.35 | -3.7 | -99.79 | 152.8 | 19.44 | -74.96 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -208.94 | -169.25 | -157.41 | -99.91 | -80.18 | -54.29 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | - | - | - | -11276.52% | -3442.76% | -289.71% |
Free Cash Flow Per Share | -2.80 | -2.64 | -3.35 | -14.49 | -23.78 | -20.64 |
Levered Free Cash Flow | -89.05 | -103.85 | -66.57 | -9.61 | -50.01 | -30.62 |
Unlevered Free Cash Flow | -89.05 | -103.85 | -66.57 | -9.61 | -50.01 | -30.62 |